$6.74
0.02[0.30%]
At close: May 31
$6.74
0[0.00%]
After Hours: 4:00PM EDT
Fractyl Health
(NASDAQ:GUTS)Latest News for Fractyl Health Stock (NASDAQ:GUTS)
Fractyl Health Stock (NASDAQ: GUTS)
Categories: All
Monday, May 20, 2024
Monday, May 13, 2024
- Fractyl Health Q1 2024 GAAP EPS $(0.17) Up From $(7.87) YoY, Sales $33.000K Up From $5.000K YoYBenzinga Newsdesk - May 13, 2024, 6:12PM
- Fractyl Health Q1 Sales $33.000K Up From $5.000K YoYBenzinga Newsdesk - May 13, 2024, 4:06PM
- Fractyl Health Presents Clinical Update on Revita German Real-World Registry In Advanced Type 2 Diabetes PatientsBenzinga Newsdesk - May 13, 2024, 6:10AM
Wednesday, April 03, 2024
Tuesday, April 02, 2024
- Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Apr 2, 2024, 1:23PM
- Fractyl Health shares are trading lower amid possible volatility. The company yesterday initially spiked after it announced FDA IDE approval for the Revita Remain-1 pivotal study and then rebounded after reporting Q4 financial results.Benzinga Newsdesk - Apr 2, 2024, 11:46AM
- Fractyl Health On April 1 Reported Q4 Adj EPS $(8.02) Down From $(7.39) YoY, Sales $7.00KBenzinga Newsdesk - Apr 2, 2024, 7:53AM
- PVH Posts Q4 Results, Joins Humana, CVS Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAvi Kapoor - Apr 2, 2024, 6:26AM
Monday, April 01, 2024
- Fractyl Health shares are trading lower amid volatility after the company reported Q4 financial results.Benzinga Newsdesk - Apr 1, 2024, 9:30AM
- Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Apr 1, 2024, 8:08AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Apr 1, 2024, 8:08AM
- Fractyl Says Its Existing Cash And Cash Equivalents Of $33.2M, And Approximately $100.3M In IPO Proceeds Are Expected To Provide A Cash Runway Through 2025Benzinga Newsdesk - Apr 1, 2024, 7:25AM
- Fractyl Health shares are trading higher after the company received FDA IDE approval for Revita Remain-1 study for obesity after discontinuation of GLP-1 based drugs.Benzinga Newsdesk - Apr 1, 2024, 6:15AM
- The FDA Approves Fractyl Health's Investigational Device Exemption To Study Revita's Efficacy In Maintaining Weight Loss Following The Discontinuation Of GLP-1 Receptor AgonistBenzinga Newsdesk - Apr 1, 2024, 6:02AM
Tuesday, March 19, 2024
Tuesday, March 12, 2024
- Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical DataVandana Singh - Mar 12, 2024, 10:53AM
- Fractyl Health shares are trading higher following preclinical findings for the company's RJVA-001 gene therapy candidate.Benzinga Newsdesk - Mar 12, 2024, 8:47AM
- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the Db/Db Mouse Model of Diabetes and ObesityBenzinga Newsdesk - Mar 12, 2024, 8:40AM
Wednesday, February 28, 2024
Friday, February 02, 2024
- Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for QuotationBenzinga Newsdesk - Feb 2, 2024, 10:10AM
- Fractyl Health Prices Initial Public Offering Of 7,333,333 Common Shares At $15/Share For Gross Proceeds Of ~$110MBenzinga Newsdesk - Feb 2, 2024, 1:30AM